CD38 CAR-NK Cells for Tumor-Specific Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using chimeric antigen receptors (CARs) on T cells require antigen priming and have limited efficacy against solid tumors, while natural killer (NK) cells lack antigen specificity and can provide robust cytotoxicity without antigen priming.
Innovation Solution
Engineering NK cells with chimeric antigen receptors (CARs) that target cancer-associated antigens like CD38, combined with modifications for increased cytotoxic activity, such as reduced expression of TRAIL receptors and enhanced E-selectin ligands, to enhance their therapeutic efficacy against cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CARs are developed to target cytotoxic T cells to particular cell types and tissues, then antigen specificity is introduced to immune effector cells, but antigen priming is required and efficacy against solid tumors is limited
Solution Approach 1:
The patent merges the antigen specificity of CARs with the antigen-independent cytotoxicity of NK cells by engineering NK cells to express CARs. This combination allows the immune effector cells to target specific cancer-associated antigens (such as CD38, CD19, CD20) while maintaining the ability to exert robust cytotoxicity without requiring antigen priming, thus resolving the contradiction between specificity and productivity.
Solution Approach 2:
The patent modifies the functional parameters of NK cells by introducing CARs that change their antigen recognition capability. The engineered NK cells now possess both the antigen specificity parameter (through CAR binding to cancer-associated antigens) and the cytotoxicity parameter (through retention of NK-mediated killing mechanisms), eliminating the need for antigen priming while maintaining effectiveness against solid tumors.
2Productivity
If NK cells are used for cancer treatment, then robust cytotoxicity is achieved without antigen priming, but lack of antigen specificity reduces effectiveness against certain cancer types
Solution Approach 1:
The patent combines the cytotoxicity capability of NK cells with the antigen specificity of CARs. The engineered NK cells express CARs that specifically bind to cancer-associated antigens, enabling them to distinguish between normal and cancerous cells while maintaining their robust cytotoxic activity without requiring prior antigen priming.
Solution Approach 2:
The patent applies local quality by directing the CAR expression specifically on NK cells rather than using it on T cells. This allows the cytotoxic function to be localized to the NK cell lineage, which naturally possesses potent cytotoxic mechanisms, while the CAR provides targeted recognition. The intracellular signaling domains of the CAR are specifically designed to activate NK cell cytotoxic pathways.
3Measurement precision
If CARs are engineered with high affinity for cancer antigens, then targeting precision is improved, but cytotoxicity towards normal cells increases
Solution Approach 1:
The patent applies local quality by utilizing the natural tissue distribution and functional characteristics of NK cells. NK cells are predominantly found in peripheral blood and have a natural tendency to target certain tumor types, providing an inherent safety margin. The CAR expression on NK cells enhances their targeting precision for cancer-associated antigens while their natural biology provides a buffer against off-target effects compared to using CAR-T cells.
Solution Approach 2:
The patent modifies the affinity parameter of the CAR targeting domain to optimize the balance between cancer cell targeting and normal cell sparing. By carefully selecting and tuning the CAR's binding affinity for cancer-associated antigens, the system achieves sufficient precision to effectively target tumors while maintaining lower cytotoxicity towards normal cells that express low or absent levels of the target antigen.
Data Source
AI summary
Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.